SiBone (SIBN) Competitors

National Vision presently has a consensus target price of $31.21, suggesting a potential upside of 36.55%. SiBone has a consensus target price of $24.00, suggesting a potential upside of 81.05%. Given SiBone's stronger consensus rating and higher possible upside, analysts plainly believe SiBone is more favorable than National Vision.

National Vision has a net margin of 1.49% compared to SiBone's net margin of -9.41%. National Vision's return on equity of 5.15% beat SiBone's return on equity.

In the previous week, SiBone had 4 more articles in the media than National Vision. MarketBeat recorded 8 mentions for SiBone and 4 mentions for National Vision. National Vision's average media sentiment score of 0.93 beat SiBone's score of 0.42 indicating that National Vision is being referred to more favorably in the media.

National Vision has higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than National Vision, indicating that it is currently the more affordable of the two stocks.

98.1% of SiBone shares are held by institutional investors. 2.7% of National Vision shares are held by company insiders. Comparatively, 3.9% of SiBone shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

National Vision has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500. Comparatively, SiBone has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500.

Establishment Labs presently has a consensus target price of $86.86, suggesting a potential upside of 17.07%. SiBone has a consensus target price of $24.00, suggesting a potential upside of 81.05%. Given SiBone's stronger consensus rating and higher possible upside, analysts plainly believe SiBone is more favorable than Establishment Labs.

SiBone has a net margin of -9.41% compared to Establishment Labs' net margin of -24.19%. SiBone's return on equity of -11.01% beat Establishment Labs' return on equity.

In the previous week, Establishment Labs had 5 more articles in the media than SiBone. MarketBeat recorded 13 mentions for Establishment Labs and 8 mentions for SiBone. Establishment Labs' average media sentiment score of 0.42 beat SiBone's score of 0.42 indicating that Establishment Labs is being referred to more favorably in the media.

SiBone has lower revenue, but higher earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than SiBone, indicating that it is currently the more affordable of the two stocks.

72.9% of Establishment Labs shares are held by institutional investors. Comparatively, 98.1% of SiBone shares are held by institutional investors. 10.0% of Establishment Labs shares are held by company insiders. Comparatively, 3.9% of SiBone shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Establishment Labs has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500. Comparatively, SiBone has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500.

86.4% of Artivion shares are held by institutional investors. Comparatively, 98.1% of SiBone shares are held by institutional investors. 6.3% of Artivion shares are held by company insiders. Comparatively, 3.9% of SiBone shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Artivion presently has a consensus target price of $51.00, suggesting a potential upside of 47.44%. SiBone has a consensus target price of $24.00, suggesting a potential upside of 81.05%. Given SiBone's higher probable upside, analysts clearly believe SiBone is more favorable than Artivion.

Artivion has a net margin of 2.21% compared to SiBone's net margin of -9.41%. Artivion's return on equity of 7.43% beat SiBone's return on equity.

In the previous week, SiBone had 5 more articles in the media than Artivion. MarketBeat recorded 8 mentions for SiBone and 3 mentions for Artivion. Artivion's average media sentiment score of 0.45 beat SiBone's score of 0.42 indicating that Artivion is being referred to more favorably in the media.

Artivion has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500. Comparatively, SiBone has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500.

Artivion has higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than Artivion, indicating that it is currently the more affordable of the two stocks.

Inspire Medical Systems has a net margin of 14.33% compared to SiBone's net margin of -9.41%. Inspire Medical Systems' return on equity of 10.66% beat SiBone's return on equity.

In the previous week, Inspire Medical Systems had 25 more articles in the media than SiBone. MarketBeat recorded 33 mentions for Inspire Medical Systems and 8 mentions for SiBone. Inspire Medical Systems' average media sentiment score of 0.65 beat SiBone's score of 0.42 indicating that Inspire Medical Systems is being referred to more favorably in the media.

Inspire Medical Systems has higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than Inspire Medical Systems, indicating that it is currently the more affordable of the two stocks.

94.9% of Inspire Medical Systems shares are held by institutional investors. Comparatively, 98.1% of SiBone shares are held by institutional investors. 2.2% of Inspire Medical Systems shares are held by company insiders. Comparatively, 3.9% of SiBone shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Inspire Medical Systems presently has a consensus target price of $85.00, suggesting a potential upside of 79.36%. SiBone has a consensus target price of $24.00, suggesting a potential upside of 81.05%. Given SiBone's stronger consensus rating and higher probable upside, analysts clearly believe SiBone is more favorable than Inspire Medical Systems.

Inspire Medical Systems has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Comparatively, SiBone has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500.